This observational study aims to better understand how the FDA-approved medication Edaravone (also known as Radicava) works in people with Amyotrophic Lateral Sclerosis (ALS). Researchers want to find out if certain types of ALS patients might benefit most from this medication and to determine the best treatment duration. You may be eligible if you are between 18 and 85 years old, have a diagnosis of ALS, are not on other experimental treatments, and have not previously taken Edaravone. The study will measure specific markers in your body (biomarkers) to understand how Edaravone affects oxidative stress and antioxidant capacity over 6 months. This study does not provide Edaravone; it is prescribed as part of your regular care.

Study design

This is an observational study planning to enroll 160 participants. It is not testing a new medication but rather observing the effects of an already approved drug.

What's involved

You would provide blood, urine, and spinal fluid samples. These samples will be collected to look for biomarkers related to oxidative stress and antioxidant capacity.

Compensation

Not stated in the trial record.

Follow-up

The primary goal is to define biomarkers at 6 months, suggesting follow-up for at least this duration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.